Incyte INCY
- Market cap
- $24.3B
- PE
- 15.3×
- 10y median 36.5×
- Forward PE
- 51.3×
- 10y median 31.7×
- Price to sales
- 4.2×
- EV/EBIT
- 28.3×
- Revenue, 12 months
- $5.8B
- +27% on a year ago
- Net margin
- 27.7%
- Free cash flow yield
- 7.9%
Incyte trades at 15.3× trailing earnings, cheaper than 95% of the last ten years. Revenue was $5.8B over the last twelve months, up 27% on a year earlier with a 28% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $919M+12% | $1B+9% | $880.9M+9% | $1B+9% | $1.1B+24% | $1.2B+16% | $1.1B+20% | $1.2B+17% | $1.4B+20% | $1.5B+28% | $1.3B+21% | $1.7B+38% | |
| Cost of revenue | $60.1M+10% | $69.8M+18% | $61M+7% | $76.6M+12% | $86M+43% | $88.5M+27% | $73.2M+20% | $78.8M+3% | $99M+15% | $121.2M+37% | $104.5M+43% | $105M+33% |
| Gross profit | $858.9M+12% | $943.6M+9% | $819.9M+9% | $967.1M+9% | $1.1B+23% | $1.1B+16% | $979.7M+20% | $1.1B+18% | $1.3B+20% | $1.4B+27% | $1.2B+19% | $1.6B+38% |
| R&D | $375.7M−2% | $444.5M−11% | $429.3M+6% | $1.1B+184% | $573.2M+53% | $466M+5% | $437.3M+2% | $494.9M−57% | $506.6M−12% | $611.4M+31% | $515.9M+18% | $517M+5% |
| SG&A | $267.9M+1% | $293.9M+8% | $300.3M−5% | $306M+8% | $309.2M+15% | $326.7M+11% | $325.7M+9% | $331M+8% | $329.1M+6% | $390.4M+20% | $328.1M+1% | $351.7M+6% |
| $214.7M+55% | $187.3M+167% | $91.9M+271% | −$478.1M | $146.1M−32% | $301.5M+61% | $205.2M+123% | $530.3M | $443.5M+204% | $335.9M+11% | $301.1M+47% | $697.9M+32% | |
| Interest expense | $623K−3% | $804K+21% | $430K−8% | $657K+0% | $774K+24% | $419K−48% | $660K+54% | $594K−10% | $592K−24% | $582K+39% | $569K−14% | $582K−2% |
| Pre-tax income | $233.8M+57% | $271M+236% | $236.2M+355% | −$389.8M | $156.5M−33% | $313.7M+16% | $234.2M−1% | $558M | $482.3M+208% | $389.9M+24% | $343.6M+47% | $751.5M+35% |
| $62.5M+75% | $69.9M+34% | $66.6M+121% | $54.8M−26% | $50.1M−20% | $112.5M+61% | $76M+14% | $153M+179% | $58.1M+16% | $90.7M−19% | $40.3M−47% | $165.9M+8% | |
| Net income | $171.3M+52% | $201.1M+607% | $169.5M+681% | −$444.6M | $106.5M−38% | $201.2M+0% | $158.2M−7% | $405M | $424.2M+298% | $299.3M+49% | $303.3M+92% | $585.6M+45% |
| $0.76+52% | $0.89+585% | $0.75+650% | −$2.04 | $0.54−29% | $1.02+15% | $0.80+7% | $2.04 | $2.11+291% | $1.46+43% | $1.47+84% | $2.81+38% | |
| 226.2M+1% | 226.4M+1% | 227.2M+1% | 218.2M−3% | 195.8M−13% | 196.7M−13% | 198.2M−13% | 198.7M−9% | 201.4M+3% | 204.5M+4% | 206.8M+4% | 208.2M+5% |
Gross profit: 58 periods, Q1 FY12 to Q2 FY26: not printed by the filing, worked out from its own lines.
Net income: 28 periods, Q3 FY10 to Q4 FY17: not printed by the filing, worked out from its own lines.
EPS, diluted: 8 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY10 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY11 and Q4 FY14: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $1.5B | $1.4B to $1.5B | −$3.93 | −$5.37 to −$2.91 | 11 |
| Q4 FY26 | $1.5B | $1.5B to $1.6B | $1.92 | $1.61 to $2.26 | 11 |
| Q1 FY27 | $1.4B | $1.3B to $1.4B | $1.69 | $1.60 to $1.79 | 4 |
| Q2 FY27 | $1.5B | $1.5B to $1.6B | $2.09 | $1.99 to $2.19 | 1 |
| Q3 FY27 | $1.6B | $1.5B to $1.6B | $2.20 | $2.09 to $2.29 | 1 |
| Q4 FY27 | $1.7B | $1.6B to $1.7B | $2.47 | $2.35 to $2.58 | 1 |
| Q1 FY28 | $1.5B | $1.4B to $1.5B | $2.22 | $2.12 to $2.32 | 2 |
| Q2 FY28 | $1.7B | $1.6B to $1.7B | $2.86 | $2.72 to $2.99 | 2 |
Peers
Companies in Biotechnology nearest Incyte's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| INCYIncyte | $24.3B | 15.3× | 36.5× | 51.3× | 4.2× | +27% | 27.7% |
| UTHRUnited Therapeutics | $25.9B | 21.6× | 14.2× | 22.6× | 8.2× | +2% | 41.6% |
| ALNYAlnylam Pharmaceuticals | $21.2B | 26.7× | 68.2× | 18.9× | 4.4× | +95% | 16.8% |
| EXELExelixis | $17.4B | 22.1× | 22.7× | n/m | 7.1× | +9% | 35.3% |
| NBIXNeurocrine Biosciences | $14.8B | 21.3× | 42.6× | n/m | 4.4× | +34% | 20.9% |
| HALOHalozyme Therapeutics | $14.6B | 38.5× | 21.3× | n/m | 8.8× | +41% | 24.9% |
| ONCBeOne Medicines | $40.2B | 63.2× | 67.6× | 45.0× | 6.6× | +34% | 10.7% |
| TECHBIO-TECHNE | $11.4B | 63.2× | 62.0× | n/m | 9.4× | −0% | 15.0% |
| RGENRepligen | $9.8B | 237× | 123× | n/m | 12.4× | +16% | 5.3% |
| KRYSKrystal Biotech | $8.8B | 37.1× | 42.5× | n/m | 19.9× | +23% | 54.8% |
| REGNRegeneron Pharmaceuticals | $100B | 24.0× | 19.7× | 15.1× | 6.4× | +9% | 27.9% |
| Peer median | $16.1B | 31.9× | 42.6× | 20.7× | 7.7× | +20% | 22.9% |
More on Incyte
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #8of 92Healthcare stocks cheapest against their own PE history
- #2of 17Biotech stocks with the highest free cash flow yield
- #3of 16Biotech stocks with the lowest PE ratio
- #8of 29Biotech stocks with the highest profit margins
- #5of 14Biotech stocks with the fastest earnings growth
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .